Study Objective To evaluate the steady‐state pharmacokinetic and pharmacodynamic
parameters of piperacillin in morbidly obese, surgical intensive care patients. Design Open …

The treatment of infections in critically ill obese and morbidly obese patients is challenging
because of the combined physiological changes that result from obesity and critical illness …

Objective: To report pharmacokinetic alterations and optimal dosing of piperacillin/
tazobactam in an obese patient. Case Summary: A 39-year-old morbidly obese (weight 167 …

Objective: Obesity and critical illness modify pharmacokinetics of antibiotics, but piperacillin-
tazobactam continuous IV infusion pharmacokinetics has been poorly studied in obese …

The study objective was to evaluate steady-state pharmacokinetics and pharmacodynamics
of piperacillin and tazobactam administered by prolonged infusion in obese patients …

The study objective was to evaluate the population pharmacokinetics and
pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in …

Piperacillin-tazobactam is a potent β-lactam/β-lactamase inhibitor antibiotic commonly
prescribed in the intensive care unit setting. Admitted patients often show large variability in …

Study Objective. To determine the appropriate compartmental and noncompartmental
pharmacokinetic parameters for intravenous piperacillin and tazobactam. Design …

Abstract Background and Objectives Although dose optimization studies have been
performed for piperacillin and tazobactam separately, a combined integral analysis is not yet …

Objectives: We investigated the population pharmacokinetics and pharmacodynamics of
piperacillin and tazobactam in hospitalized patients. Patients and methods: A multicentre …